Tegumentary manifestations of Noonan and Noonan-related syndromes.

OBJECTIVES: Noonan and Noonan-related syndromes are common autosomal dominant disorders with neuro-cardio-facial-cutaneous and developmental involvement. The objective of this article is to describe the most relevant tegumentary findings in a cohort of 41 patients with Noonan or Noonan-related syndromes and to detail certain aspects of the molecular mechanisms underlying ectodermal involvement. METHODS: A standard questionnaire was administered. A focused physical examination and a systematic review of clinical records was performed on all patients to verify the presence of tegumentary alterations. The molecular analysis of this cohort included sequencing of the following genes in all patients: PTPN1, SOS1, RAF1, KRAS, SHOC2 and BRAF. RESULTS: The most frequent tegumentary alterations were xeroderma (46%), photosensitivity (29%), excessive hair loss (24%), recurrent oral ulcers (22%), curly hair (20%), nevi (17%), markedly increased palmar and plantar creases (12%), follicular hyperkeratosis (12%), palmoplantar hyperkeratosis (10%), café-au-lait spots (10%) and sparse eyebrows (7%). Patients with mutations in PTPN11 had lower frequencies of palmar and plantar creases and palmar/plantar hyperkeratosis compared with the other patients. CONCLUSIONS: We observed that patients with mutations in genes directly involved in cell proliferation kinase cascades (SOS1, BRAF, KRAS and RAF1) had a higher frequency of hyperkeratotic lesions compared with patients with mutations in genes that have a more complex interaction with and modulation of cell proliferation kinase cascades (PTPN11).

Tegumentary manifestations of Noonan and Noonan-related syndromes

OBJECTIVES: Noonan and Noonan-related syndromes are common autosomal dominant disorders with neuro-cardio-facial-cutaneous and developmental involvement. The objective of this article is to describe the most relevant tegumentary findings in a cohort of 41 patients with Noonan or Noonan-related syndromes and to detail certain aspects of the molecular mechanisms underlying ectodermal involvement. METHODS: A standard questionnaire was administered. A focused physical examination and a systematic review of clinical records was performed on all patients to verify the presence of tegumentary alterations. The molecular analysis of this cohort included sequencing of the following genes in all patients: PTPN1, SOS1, RAF1, KRAS, SHOC2 and BRAF. RESULTS: The most frequent tegumentary alterations were xeroderma (46%), photosensitivity (29%), excessive hair loss (24%), recurrent oral ulcers (22%), curly hair (20%), nevi (17%), markedly increased palmar and plantar creases (12%), follicular hyperkeratosis (12%), palmoplantar hyperkeratosis (10%), café-au-lait spots (10%) and sparse eyebrows (7%). Patients with mutations in PTPN11 had lower frequencies of palmar and plantar creases and palmar/plantar hyperkeratosis compared with the other patients. CONCLUSIONS: We observed that patients with mutations in genes directly involved in cell proliferation kinase cascades (SOS1, BRAF, KRAS and RAF1) had a higher frequency of hyperkeratotic lesions compared with patients with mutations in genes that have a more complex interaction with and modulation of cell proliferation kinase cascades (PTPN11). .

Ocular manifestations of Noonan syndrome.

PURPOSE: To describe the ophthalmological characteristics in a group of Noonan syndrome patients with proven mutations in the PTPN11 gene. METHODS: Thirty-five Noonan syndrome patients with PTPN11 gene mutations underwent ophthalmological exams, which consisted of external inspection, slit-lamp biomicroscopy examination and an ophthalmoscopic examination after instillation of 1.0% tropicamide or 1.0% cyclopentolate. RESULTS: All 35 patients had at least one abnormality upon ophthalmological examination. The eyelid and external eye abnormalities were the prevailing features, followed by prominent corneal nerves on slit-lamp exam. Fundus changes were detected in 8% of the subjects, mainly associated with high myopia. No statistically significant differences were observed among the patients presenting specific mutations in the PTPN11 gene. CONCLUSIONS: The current study further supports the finding that ocular symptoms account for a large fraction of the clinical manifestations of NS. Additional characteristics are described here. The roles for the various mutations of PTPN11 in ocular development are yet to be established.

Determinantes genéticos na síndrome de Noonan e nas síndromes Noonan-like: investigação clínica e molecular / Genetic determinants in Noonan syndrome and in Noonan-like syndromes: clinical and molecular study

A síndrome de Noonan (SN) é uma doença de herança autossômica, relativamente frequente na população e que apresenta heterogeneidade genética. Caracteriza-se por dismorfismos faciais, baixa estatura, pescoço curto/alado, alterações cardíacas, deformidades esternais e criptorquia. A SN apresenta sobreposição dos achados clínicos com outras síndromes mais raras, denominadas síndromes Noonan-like (SNL): síndrome cardio-facio-cutânea (CFC), síndrome de Costello (SC), neurofibromatose-síndrome de Noonan (NFSN), síndrome de Noonan com manchas lentiginosas/síndrome de LEOPARD (SL), síndrome de Noonan-like com perda de cabelos anágenos (SNL-PCA) e síndrome de Noonan-like com leucemia mielomonocítica juvenil (SNL-LMMJ). As SN e SNL decorrem de mutações em genes pertencentes à via de sinalização RAS/MAPK alguns dos quais são protooncogenes, o que tem despertado o interesse na caracterização do risco de desenvolvimento de neoplasias nessas síndromes. Os objetivos deste estudo visam o sequencimento conjunto dos genes PTPN11, SOS1, RAF1, KRAS, SHOC2, BRAF e HRAS em pacientes com diagnóstico clínico das SN e SNL a fim de: determinar a frequência de mutação; estabelecer uma correlação genótipo-fenótipo; estabelecer um fluxograma para o estudo molecular a partir dos hotspots; e avaliar se a variabilidade fenotípica apresentada nos pacientes com SN pode ser explicada pela presença de mutações em mais de um gene da via RAS/MAPK. Foram avaliados 194 probandos - 152 com SN e 42 com SNL (19 CFC, 15 NFNS, 4 CS e 4 LS). Mutações foram identificadas em 99 pacientes 80 com SN (53%); 19 com SNL. Apenas um paciente com SN apresentou mutação em dois genes da via RAS/MAPK (PTPN11 e SOS1). O estudo molecular na SN mostrou, assim como na literatura, um maior envolvimento do gene PTPN11 (34%), seguido dos genes SOS1 (12%) e RAF1 (7%). A comparação dos achados clínicos, levando em consideração as alterações gênicas, também confirma as correlações já descritas na literatura; entre elas...

Noonan syndrome (NS) is a relatively common, autosomal dominant disease that presents a marked genetic heterogeneity. It is characterized by facial dysmorphisms, short stature, webbed/short neck, cardiac abnormalities, esternal anomalies and cryptorchidism. NS shows clinical overlap of some of its findings with other rarer syndromes, known as Noonan-like syndromes (NLS): cardio-facio-cutaneous syndrome (CFC), Costello syndrome (CS), neurofibromatosis-Noonan syndrome (NFNS), Noonan syndrome with lentiginous stains/LEOPARD syndrome (LS), Noonan-like syndrome with loose anagen hair (NLS-LAH) and Noonan-like syndrome with juvenile myelomonocytic leukemia (NLS-JMML). NS and NLS are related to mutations in genes belonging of RAS-MAPK signaling pathway. Some of these genes are classified as proto-oncogenes. This fact also arouses the interest in the characterization of the risk for cancer development in this group of patients. The objectives of this study are to sequence the genes associated with NS and NLS (PTPN11, SOS1, RAF1, KRAS, SHOC2, HRAS and BRAF) in patients that fulfilled clinical diagnostic criteria for NS or NLS to: determine the frequency of the mutations; establish a genotype-phenotype correlation; estabilish a flowchart for molecular study from the hotspots; and evaluate when the phenotypic variability presented in NS patients can be explained by the presence of mutations in more than one gene of the RAS/MAPK pathway. This study evaluated 194 probands 152 with NS e 42 with NLS (19 CFC, 15 NFSN, 4 SC e 4 SL). Mutations were identified in 99 patients 80 with NS (53%), 19 with NLS. Only one patient presented mutation in two different genes of the RAS/MAPK pathway (PTPN11 and SOS1). The molecular analysis showed a predominance of mutations in the PTPN11 gene (34%), followed by the SOS1 (12%) and RAF1 (7%) genes in patients with NS, in accordance with the literature. Patients with NS and mutation in the: PTPN11 gene, presented a higher frequency of...

Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype? / Coocorrência de mutações nos genes PTPN11 e SOS1 na síndrome de Noonan: este achado prediz um fenótipo mais grave?

Noonan syndrome (NS) is an autosomal dominant disorder, with variable phenotypic expression, characterized by short stature, facial dysmorphisms and heart disease. Different genes of the RAS/MAPK signaling pathway are responsible for the syndrome, the most common are: PTPN11, SOS1, RAF1, and KRAS. The objective of this study was to report a patient with Noonan syndrome presenting mutations in two genes of RAS/MAPK pathway in order to establish whether these mutations lead to a more severe expression of the phenotype. We used direct sequencing of the PTPN11, SOS1, RAF1, and KRAS genes. We have identified two described mutations in heterozygosity: p.N308D and p.R552G in the genes PTPN11 and SOS1, respectively. The patient has typical clinical features similar to the ones with NS and mutation in only one gene, even those with the same mutation identified in this patient. A more severe or atypical phenotype was not observed, suggesting that these mutations do not exhibit an additive effect.

A síndrome de Noonan (SN) é uma doença gênica autossômica dominante, com expressão clínica variável, caracterizada por baixa estatura, dismorfismos faciais e cardiopatia. Diferentes genes da via de sinalização RAS/MAPK são responsáveis pela síndrome, sendo as mais frequentes: PTPN11, SOS1, RAF1 e KRAS. O objetivo deste estudo foi relatar um paciente com SN que apresenta mutações em dois genes da via RAS/MAPK a fim de estabelecer se essas mutações levam a uma expressão mais grave do fenótipo. Utilizou-se sequenciamento direto dos genes PTPN11, SOS1, RAF1 e KRAS. Foram identificadas duas mutações em heterozigose previamente descritas: p.N308D e p.R552G nos genes PTPN11 e SOS1, respectivamente. A paciente apresenta quadro clínico típico semelhante ao dos pacientes com SN e mutação em um único gene, mesmo naqueles com a mesma mutação identificada na paciente. Não foi observado um fenótipo mais grave ou atípico na paciente, sugerindo que as mutações não apresentam um efeito aditivo.

PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.

Noonan and Noonan-like syndromes are disorders of dysregulation of the rat sarcoma viral oncogene homolog (RAS)-mitogen-activated protein kinase signaling pathway. In Noonan syndrome (NS), four genes of this pathway (PTPN11, SOS1, RAF1, and KRAS) are responsible for roughly 70% of the cases. We analyzed PTPN11 and KRAS genes by bidirectional sequencing in 95 probands with NS and 29 with Noonan-like syndromes, including previously reported patients already screened for PTPN11 gene mutations. In the new patients with NS, 20/46 (43%) showed a PTPN11 gene mutation, two of them novel. In our total cohort, patients with NS and a PTPN11 mutation presented significantly higher prevalence of short stature (p = 0.03) and pulmonary valve stenosis (p = 0.01), and lower prevalence of hypertrophic cardiomyopathy (p = 0.01). Only a single gene alteration, of uncertain role, was found in the KRAS gene in an NS patient also presenting a PTPN11 gene mutation. We further analyzed the influence in clinical variability of three frequent polymorphisms found in the KRAS gene and no statistically significant difference was observed among the frequency of clinical findings regarding the studied polymorphisms.

Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?

Noonan syndrome (NS) is an autosomal dominant disorder, with variable phenotypic expression, characterized by short stature, facial dysmorphisms and heart disease. Different genes of the RAS/MAPK signaling pathway are responsible for the syndrome, the most common are: PTPN11, SOS1, RAF1, and KRAS. The objective of this study was to report a patient with Noonan syndrome presenting mutations in two genes of RAS/MAPK pathway in order to establish whether these mutations lead to a more severe expression of the phenotype. We used direct sequencing of the PTPN11, SOS1, RAF1, and KRAS genes. We have identified two described mutations in heterozygosity: p.N308D and p.R552G in the genes PTPN11 and SOS1, respectively. The patient has typical clinical features similar to the ones with NS and mutation in only one gene, even those with the same mutation identified in this patient. A more severe or atypical phenotype was not observed, suggesting that these mutations do not exhibit an additive effect.

Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene.

Costello syndrome is an autosomal dominant disorder comprising growth deficiency, mental retardation, curly hair, coarse facial features, nasal papillomata, low-set ears with large lobes, cardiac anomalies, redundant skin in palms and soles with prominent creases, dark skin, and propensity to certain solid tumors. HRAS mutations have been implicated in approximately 85% of the affected cases. The clinical overlap among Costello, Noonan, and cardiofaciocutaneous syndromes is now better understood given their common molecular background, such that all these syndromes constitute a class of disorders caused by deregulated RAS-MAPK signaling. We report on a novel KRAS gene mutation in a patient presenting the clinical features typical of Costello syndrome and the additional findings seen in Noonan syndrome. This description emphasizes that a subset of patients with Costello syndrome could harbor mutations in other genes involved in the RAS-MAPK signaling.